Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Clinical Cancer Research

Volumn 22, Issue 10, 2016, Pages 2342-2350

  Van Marïette, I E Poelgeest ^a   Marij, J P Welters ^a   Renee, Vermeij ^b   Linda, F M Stynenbosch ^a   Nikki, M Loof ^a   Dorien, Berends Van Der Meer ^a   Margriet, Lowik ^a   Ineke, Hamming ^b   Van Edith, M G Esch ^a   Bart, W J Hellebrekers ^c   Van Marc, Beurden ^d   Henk, W Schreuder ^e   Marjolein, J Kagie ^f   Trimbos, Baptist M Z ^a   Lorraine, M Fathers ^a   Toos, Daemen ^b   Harry, Hollema ^b   Valentijn, Rob P M ^a   Jaap, Oostendorp ^a   Hanneke, Oude Elberink ^b   Gertjan, J Fleuren ^a   Tjalling, Bosse ^a   Gemma, G Kenter ^g   Theo, Stijnen ^a   Hans, W Nijman ^b   Cornelis, J M Melief ^a,h   Sjoerd, Der Burg H ^a   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f MEDICAL CENTER HAAGLANDEN   (Netherlands)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h ISA Pharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; ISA 101; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; CANCER VACCINE; GAMMA INTERFERON; ONCOPROTEIN; WART VIRUS VACCINE;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE ULCER; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT RESPONSE; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRAL CLEARANCE; VULVA TUMOR; VULVAR INTRAEPITHELIAL NEOPLASIA; CARCINOMA IN SITU; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PROCEDURES; UTERINE CERVIX TUMOR; VACCINATION; VAGINA TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AMINOQUINOLINES; CANCER VACCINES; CARCINOMA IN SITU; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON-GAMMA; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 84968735713     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2594     Document Type: Article

References (23)

1. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009;113:917-24.
2. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-22.
3. van der Burg SH, Arens R, Melief CJ. Immunotherapy for persistent viral infections and associated disease. Trends Immunol 2011;32:97-103.
4. van Esch EM, Welters MJ, Jordanova ES, Trimbos JB, van der Burg SH, van Poelgeest MI. Treatment failure in patients with HPV16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Rev Vaccines 2012;11:821-40.
5. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005;97:645-51.
6. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, et al.Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010;107:11895-9.
7. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al.Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
8. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, et al.Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87.
9. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al.Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-77.
10. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, van der Burg SH, et al.Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 2010;70:8339-46.
11. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004;4:9.
12. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-60.
13. Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, et al.Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917-27.
14. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, et al.Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008;358:1465-73.
15. van Poelgeest MI, van SM, van BM, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, et al.Detection of human papillomavirus (HPV) 16-specificCD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005;11:5273-80.
16. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61.
17. Nikkels AF, Nikkels-Tassoudji N, Pierard GE. Cutaneous adverse reactions following anti-infective vaccinations. Am J Clin Dermatol 2005;6:79-87.
18. Ferenczi K, Berke A, Cichon D, Jurzyk R, Somach SC. Varicella-zoster virus vaccination-induced granulomatous dermatitis. J Am Acad Dermatol 2014;71:e131-32.
19. de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, Lowik MJ, Berends-van der Meer DM, van der Minne CE, et al.The long-term immune response after HPV16 peptide vaccination in women with low-grade premalignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother 2014;63:147-60.
20. Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011;34:92-9.
21. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al.Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008;3:e2636.
22. van Esch EM, van Poelgeest MI, Kouwenberg S, Osse EM, Trimbos JB, Fleuren GJ, et al.Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. Int J Cancer 2015;136:E95-106.
23. van Esch EM, van Poelgeest MI, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg SH. Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPVinduced vulvar neoplasia. Int J Cancer 2015;136:E85-94.